Intercept Shares Fall After Interim Analysis On Late-Stage NASH Study
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) announced positive topline results from a new interim analysis of its ongoing pivotal Phase 3 REGENERATE trial of OCA in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH).
